Polyrotaxane-based supramolecular theranostics

Guocan Yu, Zhen Yang, Xiao Fu, Bryant C. Yung, Jie Yang, Zhengwei Mao (), Li Shao, Bin Hua, Yijing Liu, Fuwu Zhang, Quli Fan (), Sheng Wang, Orit Jacobson, Albert Jin, Changyou Gao, Xiaoying Tang, Feihe Huang () and Xiaoyuan Chen ()
Additional contact information
Guocan Yu: National Institutes of Health
Zhen Yang: National Institutes of Health
Xiao Fu: National Institutes of Health
Bryant C. Yung: National Institutes of Health
Jie Yang: Zhejiang University
Zhengwei Mao: Zhejiang University
Li Shao: Zhejiang University
Bin Hua: Zhejiang University
Yijing Liu: National Institutes of Health
Fuwu Zhang: National Institutes of Health
Quli Fan: Nanjing University of Posts & Telecommunications
Sheng Wang: National Institutes of Health
Orit Jacobson: National Institutes of Health
Albert Jin: National Institutes of Health
Changyou Gao: Zhejiang University
Xiaoying Tang: Beijing Institute of Technology
Feihe Huang: Zhejiang University
Xiaoyuan Chen: National Institutes of Health

Nature Communications, 2018, vol. 9, issue 1, 1-13

Abstract: Abstract The development of smart theranostic systems with favourable biocompatibility, high loading efficiency, excellent circulation stability, potent anti-tumour activity, and multimodal diagnostic functionalities is of importance for future clinical application. The premature burst release and poor degradation kinetics indicative of polymer-based nanomedicines remain the major obstacles for clinical translation. Herein we prepare theranostic shell-crosslinked nanoparticles (SCNPs) using a β-cyclodextrin-based polyrotaxane (PDI-PCL-b-PEG-RGD⊃β-CD-NH2) to avoid premature drug leakage and achieve precisely controllable release, enhancing the maximum tolerated dose of the supramolecular nanomedicines. cRGDfK and perylene diimide are chosen as the stoppers of PDI-PCL-b-PEG-RGD⊃β-CD-NH2, endowing the resultant SCNPs with excellent integrin targeting ability, photothermal effect, and photoacoustic capability. In vivo anti-tumour studies demonstrate that drug-loaded SCNPs completely eliminate the subcutaneous tumours without recurrence after a single-dose injection combining chemotherapy and photothermal therapy. These supramolecular nanomedicines also exhibit excellent anti-tumour performance against orthotopic breast cancer and prevent lung metastasis with negligible systemic toxicity.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-03119-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03119-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-03119-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().